Biomet Announces 2,000 U.S. Surgeons, to Date, Have Completed Training to Implant the Oxford(R) Partial Knee
2007年7月12日 - 5:40AM
ビジãƒã‚¹ãƒ¯ã‚¤ãƒ¤ï¼ˆè‹±èªžï¼‰
Biomet, Inc. (NASDAQ:BMET) announced today that Biomet Orthopedics
recently held its 19th Oxford� Partial Knee training course in the
United States, with 2,000 domestic surgeons having completed the
training, to date. Trained surgeons receive access to the
market-leading Oxford� Partial Knee with its published long-term
clinical results of 98% success at 10 years1 follow-up, a 95%
success rate at 15 years2 and 92% success reported at 20 years3.
The Oxford� Partial Knee, with its free-floating meniscal bearing
design, is the only true mobile bearing partial knee available in
the United States. The Oxford� Knee has been implanted in patients
outside the United States since 1976, but was first introduced to
the domestic market as the Oxford� Unicompartmental Knee System
during October 2004 after Biomet obtained pre-market approval from
the U.S. Food and Drug Administration earlier that year. The
primary advantages of the Oxford� Partial Knee include 75% less
bone removal, less postoperative pain and more natural motion than
a total knee replacement.4, 5 In addition, the Oxford� Knee may be
implanted utilizing a minimally invasive procedure that is designed
to allow for a more rapid recovery. One of every four
osteoarthritic knees may potentially be treated conservatively with
the Oxford� Partial Knee.1 The training sessions, which are staffed
by Oxford University designing surgeons along with faculty in the
United States, provide surgeons with practical hands-on experience
to learn the Oxford� Partial Knee surgical technique utilizing the
patented instrumentation system. The surgical technique includes
preservation of the anterior cruciate ligament in order to maintain
joint stability and natural motion. Biomet�s President and Chief
Executive Officer Jeffrey R. Binder stated, �Biomet is honored to
work with these exceptional faculty members who are passionate
about the Oxford� Partial Knee and the benefits it provides to
patients. In addition, we are pleased to offer this training to the
many talented surgeons who are making the commitment to attend
these high-level courses.� Mr. Binder continued, �We are excited
about the phenomenal market acceptance the Oxford� Knee is
receiving in the United States, as we celebrate the Oxford�
System�s 30 years of excellent clinical success outside the United
States. Importantly, the Oxford� Partial Knee is the most widely
used and clinically proven partial knee system in the world,
producing long-term survivorship results that equal those of the
most successful total knee replacements.� 1Murray D.W., Goodfellow
J.W., O'Connor J.J. The Oxford� medial unicompartmental
arthroplasty: a ten-year survival study. Journal of Bone and Joint
Surgery (British). 80(6): 983-989, 1998. 2Price A.J., Svard U. The
Oxford� Medial Unicompartmental Knee Arthroplasty Fifteen-Year
Survival Results From an independent series B.O.A. Meeting 2000,
London 3Price, A., Svard U. 20-year survival & 10 year clinical
results of the Oxford� medical UKA. In: Proceedings of the American
Academy of Orthopedic Surgeons Annual Meeting; March 22-26, 2006:
Chicago, Ill.538. 4Data on file at Biomet. 5Kim, K.T. et al.
Prospective Analysis of Oxford� Phase 3 Unicompartmental Knee
Arthroplasty. Orthopedics. 30(5 Suppl): 15-18, 2007. Oxford� is a
trademark of Biomet Manufacturing Corp. About Biomet Biomet, Inc.
and its subsidiaries design manufacture and market products used
primarily by musculoskeletal medical specialists in both surgical
and non-surgical therapy. Biomet�s product portfolio encompasses
reconstructive products, including orthopedic joint replacement
devices, bone cements and accessories, autologous therapies and
dental reconstructive implants; fixation products, including
electrical bone growth stimulators, internal and external
orthopedic fixation devices, craniomaxillofacial implants and bone
substitute materials; spinal products, including spinal stimulation
devices, spinal hardware and orthobiologics; and other products,
such as arthroscopy products and softgoods and bracing products.
Headquartered in Warsaw, Indiana, Biomet and its subsidiaries
currently distribute products in more than 100 countries.
Forward-Looking Statements This press release contains certain
statements that are �forward-looking statements� within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements are
qualified by the inherent risks and uncertainties surrounding
future expectations generally, and also may materially differ from
actual future experience involving any one or more of such
statements. Such risks and uncertainties include our ability to
develop and market new products and technologies in a timely
manner, the effect of the pending merger on Biomet�s business and
its relationship with customers, distributors, employees and
suppliers and the risk factors as set forth from time to time in
Biomet�s filings with the SEC. The inclusion of a forward-looking
statement herein should not be regarded as a representation by
Biomet that Biomet�s objectives will be achieved. Biomet undertakes
no obligation to publicly update forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information contact Daniel P. Florin, Senior Vice
President, Biomet and Chief Financial Officer at (574) 372-1687,
Greg W. Sasso, Senior Vice President, Biomet and President SBU
Operations at (574) 372-1528 or Barbara Goslee, Director, Corporate
Communications at (574) 372-1514.
Biomet (NASDAQ:BMET)
éŽåŽ» æ ªä¾¡ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 7 2024 ã¾ã§ 8 2024
Biomet (NASDAQ:BMET)
éŽåŽ» æ ªä¾¡ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 8 2023 ã¾ã§ 8 2024